0000000001125024

AUTHOR

D. Biasoni

showing 3 related works from this author

Early outcomes and complications following cardiac surgery in patients testing positive for coronavirus disease 2019: An international cohort study

2021

The outbreak of severe acute respiratory syndromecoronavirus-2, the cause of coronavirus disease 2019 (COVID-19) in December 2019 represented a global emergency accounting for more than 2.5 million deaths worldwide.1 It has had an unprecedented influence on cardiac surgery internationally, resulting in cautious delivery of surgery and restructuring of services.2 Understanding the influence of COVID-19 on patients after cardiac surgery is based on assumptions from other surgical specialties and single-center studies. The COVIDSurg Collaborative conducted a multicenter cohort study, including 1128 patients, across 235 hospitals, from 24 countries demonstrating perioperative COVID-19 infection…

Pulmonary and Respiratory MedicineMale2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)complication.ArticleNOCohort Studiesoutcomes; complications; following cardiac surgery; coronavirus disease 2019Postoperative ComplicationsCardiovascular Diseases; Cohort Studies; Female; Humans; Male; Middle Aged; SARS-CoV-2; COVID-19; Cardiac Surgical Procedures; Postoperative ComplicationsInternal medicineCardiovascular DiseasemedicineCardiac Surgical ProcedureHumansIn patientCardiac Surgical ProceduresLS7_4business.industrySARS-CoV-2COVID-19Middle AgedCardiac surgeryCardiovascular DiseasesoutcomeSurgeryFemaleCohort StudieCardiology and Cardiovascular Medicinebusinesscardiac surgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCohort studyHuman
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct

Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score

2021

The British journal of surgery 108(11), 1274-1292 (2021). doi:10.1093/bjs/znab183

Cuidado perioperatorioAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALEMedizinpulmonary complicationspreoperative screeningDatasets as TopicSurgical Procedures Operative/mortality030230 surgeryperioperative care ; surgical procedures ; operative mortality ; machine learning ; sars-cov-2Medical and Health SciencesProcediments quirúrgicsCohort StudiesMachine LearningTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineModelsProcedimientos quirúrgicosMedicine and Health SciencesCOVIDSurg Collaborative Co-authorsMedicine030212 general & internal medicineskin and connective tissue diseasesRapid Research Communication11 Medical and Health SciencesOperative/mortalitySARS-CoV-19COVID-19/mortalityStatisticalCOVID-19/mortality; Cohort Studies; Datasets as Topic; Humans; Machine Learning; Models Statistical; Risk Assessment; SARS-CoV-2; Surgical Procedures Operative/mortalityCOVID-19; Cohort Studies; Datasets as Topic; Humans; Machine Learning; SARS-CoV-2; Surgical Procedures Operative; Models Statistical; Risk AssessmentAprendizaje automáticoOperativeSurgical Procedures OperativeoutcomeOperativo[SDV.IB]Life Sciences [q-bio]/BioengineeringPatient SafetyAcademicSubjects/MED000106.4 SurgeryLife Sciences & BiomedicineHuman61medicine.medical_specialty616.9Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-.Risk AssessmentNOCOVIDSurg CollaborativeVaccine Related03 medical and health sciencesClinical ResearchBiodefenseCures perioperatòriesAprenentatge automàticMortalitatHumansOperatiusLS7_4Surgical ProceduresScience & TechnologyModels Statisticalbusiness.industrySARS-CoV-2SARS-CoV-2 infectionKirurgiPreventionnot indicatedcovid 19fungiEvaluation of treatments and therapeutic interventionsCOVID-19Perioperativecovid 19; pulmonary complications; postoperative mortality risk; SARS-CoV-2 infection; preoperative screening; vaccinationvaccinationmortalityGood Health and Well BeingMortalidadEmergency medicineSurgeryHuman medicineCohort Studiebusinesspostoperative mortality riskPerioperative care
researchProduct